Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
BIORA THERAPEUTICS, INC. (PROG) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 8-K Quarterly results
10/11/2023 8-K Quarterly results
10/06/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Investor presentation, Quarterly results
Docs: "Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results NaviCapTM targeted oral delivery platform on track for September IND filing; achieved successful device function study results in humans with phase 1-ready device BioJetTM systemic oral delivery platform device development achieved function targets while continuing to exceed bioavailability targets The company strengthened its intellectual property position with additional patents for both platforms Management will host conference call and webcast today at 4:30 PM Eastern / 1:30 PM Pacific",
"THERAPEUTIC PIPELINE PROGRAM PROGRAM INDICATION DESIGN/FEASIBILITY PRECLINICAL CLINICAL TARGETED THERAPEUTICS"
07/28/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
06/13/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
06/13/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
06/08/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/27/2023 ARS Form ARS - Annual Report to Security Holders:
04/27/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/13/2023 SC 13D/A Athyrium Opportunities 2020 LP reports a 32.7% stake in Biora Therapeutics, Inc.
03/13/2023 8-K Regulation FD Disclosure  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
02/14/2023 SC 13G ARMISTICE CAPITAL, LLC reports a 5.7% stake in Biora Therapeutics, Inc.
02/08/2023 EFFECT Form EFFECT - Notice of Effectiveness:
01/27/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
01/20/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
01/12/2023 SC 13D/A Athyrium Opportunities 2020 LP reports a 27.8% stake in Biora Therapeutics, Inc.
01/12/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Biora Therapeutics Receives Pre-IND Feedback from FDA and Provides Update on Key Programs for 2023"
01/09/2023 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "Certificate of Elimination of Series X Preferred Stock",
"Certificate of Elimination of Series X Preferred Stock"
12/30/2022 8-K Quarterly results
12/19/2022 8-K Quarterly results
12/09/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
12/09/2022 8-K Quarterly results
11/29/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
11/28/2022 8-K Quarterly results
11/23/2022 8-K Quarterly results
11/18/2022 SC 13D/A Athyrium Opportunities 2020 LP reports a 28.4% stake in Biora Therapeutics, Inc.
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/14/2022 8-K Quarterly results
11/10/2022 PRE 14A Form PRE 14A - Other preliminary proxy statements:
11/10/2022 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy